miRNA marker for diagnosis of breast cancer, application thereof and diagnostic kit

Abstract

The invention belongs to the field of biotechnologies, relates to an miRNA marker for diagnosis of breast cancer, application thereof and a diagnostic kit, provides an miRNA marker for diagnosis of breast cancer and application thereof to preparation of a breast cancer diagnosis kit and further provides a breast cancer diagnosis kit, wherein the contents of miR-146a, miR-155, Mir-21, miR-222 and miR-339 in tissues can be measured by the breast cancer diagnosis kit. The miRNA marker for diagnosis of breast cancer, application thereof and the diagnostic kit have the advantages that through a wide range of document surveys, tumor markers which possibly have potentials are screened out of documents which are published, through extensive experiments and analysis, five types of miRNA including miR-146a, miR-155, miR-21, miR-222 and miR-339 which have high diagnosis value on breast cancer are found, through development and application of the miRNA marker and the diagnostic kit, diagnosis of breast cancer can be more convenient and easier to conduct, a foundation is laid for rapidly and accurately grasping the patient condition by a clinical doctor, and help is provided for finding a novel small molecule drug target which has potential treatment value.

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to a miRNA marker for breast cancer diagnosis, its application and a diagnostic kit. Background technique [0002] Breast cancer is currently one of the most common and deadly malignant tumors in the world, and its morbidity and mortality are increasing rapidly. In order to reduce the mortality rate of breast cancer patients, in addition to reducing the incidence rate in terms of etiological prevention, improving the level of early diagnosis and the efficacy of drug treatment are two important aspects. However, the early diagnosis of lung cancer has always been a worldwide problem. At present, imaging diagnosis (B-ultrasound, mammography), chemical diagnosis (cancer response, serological and immunological indicators) and histocytological diagnosis are the three pillars of tumor diagnosis. The former has great limitations in subclinical diagnosis, while the latter two use tumor markers as...

AI Technical Summary

Problems solved by technology

[0004] Due to the diversity of breast cancer histopathology, the heterogeneity of tumor cells with the same pathology, and the complexity and polymorphism of tumor biological behavior, the diagnostic value of single marker detection for breast cancer is limited, and it can only reflect a certain disease. Many scholars at home and abroad tend to screen a variety of valuable tumor markers for joint detection in order to increase the positive rate of breast cancer diagnosis.

Although it has become a consensus that combined detection is better than single detection, not any combination can improve the positive rate of clinical diagnosis, and the conclusions on the best combination are quite inconsistent, and even the opposite results

Images